mfn-cus-disclaimer-2025

mfn-cus-disclaimer-2025

Press Release
Active Biotech announces outcome in the rights issue
2025-12-10
Regulatory
Press Release
The subscription period in Active Biotech’s rights issue begins today
2025-11-25
Regulatory
Press Release
Active Biotech publishes information document regarding rights issue
2025-11-20
Regulatory
Press Release
Active Biotech announces a fully secured rights issue of approximately SEK 70 million
2025-10-17
Regulatory
Press Release
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops
2024-04-03